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Abstract: Chronic kidney disease (CKD) is one of the fastest-growing causes of death and is predicted
to become by 2040 the fifth global cause of death. CKD is characterized by increased oxidative stress
and chronic inflammation. However, therapies to slow or prevent CKD progression remain an unmet
need. Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that plays a key role
in protection against oxidative stress and regulation of the inflammatory response. Consequently,
the use of compounds targeting Nrf2 has generated growing interest for nephrologists. Pre-clinical
and clinical studies have demonstrated that Nrf2-inducing strategies prevent CKD progression and
protect from acute kidney injury (AKI). In this article, we review current knowledge on the protective
mechanisms mediated by Nrf2 against kidney injury, novel therapeutic strategies to induce Nrf2
activation, and the status of ongoing clinical trials targeting Nrf2 in renal diseases.
Keywords: Nrf2; renal disease; acute kidney injury; oxidative stress; and inflammatory response
1. Introduction
Renal disease has been described as one of the most important public health prob-
lems due to its elevated prevalence, high mortality rates, and decreased health-related
quality of life. Renal disease may be classified as chronic kidney disease (CKD) and acute
kidney injury (AKI). CKD is related to a progressive loss of renal function, leading to
premature death or end-stage renal disease (ESRD), and subsequent dialysis or kidney
transplantation [1,2]. CKD outcome has been associated with the severity of its pathological
mechanisms, such as micro-vascular damage, inflammation, reactive oxygen species (ROS)
production, and fibrosis [3,4]. The incidence of AKI is increasing and AKI causes at least
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2 million deaths worldwide/year [5]. Pathologically, AKI is characterized by massive tubu-
lar cell death [6] that promotes an abrupt loss of renal function, leading to increased serum
creatinine and/or a decreased urine output [7,8]. There is a close relationship between AKI
and CKD since AKI accelerates the progression of CKD, and CKD patients have increased
risk to develop an AKI episode [9,10]. Moreover, after full recovery of the AKI episode,
there is increased residual risk to suffer premature death [9,11].
There are no effective treatments to prevent renal disease in high-risk populations
or to treat it once established [12]. Hence, there is an unmet need for novel therapeutic
strategies to prevent AKI and CKD development and progression. A deregulated response
to oxidative stress is considered one of the main pathogenic and aggravating factors in
renal diseases. Oxidative stress contributes to AKI, the AKI-to-CKD transition, and CKD
progression to ESRD [13]. Thus, there is a growing interest in the role of Nrf2 (nuclear
factor erythroid 2-related factor 2) in kidney disease, since Nrf2 is a master regulator
of antioxidant responses. In fact, recent studies indicate that the activation of the Nrf2
signaling pathway prevents kidney disease progression [14]. This review summarizes
current knowledge on the protective mechanisms mediated by Nrf2 against kidney injury,
novel therapeutic strategies to induce Nrf2 activation, and the status of ongoing clinical
trials targeting Nrf2 in renal diseases.
2. Nrf2 Structure and Activation
Nrf2 is a member of the basic region leucine zipper (bZIP) family of transcription
factors, and more exactly to the cap‘n’collar (CNC) subfamily. Nrf2 has seven structural
domains (Neh1 to Neh7) that have different functions [15] (Figure 1). The Neh1 domain is
constituted by a CNC-bZIP region that interacts with DNA and the small musculoaponeu-
rotic fibrosarcoma (sMaf) proteins [16]. sMaf proteins dimerize with Nrf2 and they help
Nrf2 to bind to the DNA. Moreover, this domain interacts with the E2 ubiquitin-binding
enzyme UbcM2 (an E2-type ubiquitin-binding enzyme) to regulate the stability of Nrf2 [17]
and allows DNA binding and modulation of numerous genes through its association with
ARE (antioxidant response element) sequences in specific gene promoter regions [18]. The
Neh2 domain contains the DLG (low-affinity) and ETGE (high-affinity) motifs that facilitate
the binding of Nrf2 to its negative regulator Kelch-like ECH-associated protein 1 (Keap1).
Moreover, the Neh2 domain also comprises seven lysine residues whose ubiquitination
promotes Nrf2 proteasomal degradation [19,20]. The C-terminal domain (Neh3) partici-
pates in transcriptional activation of Nrf2 via interaction with the chromodomain helicase
DNA binding protein 6 (CHD6) [21]. Moreover, the Neh3 domain in association with the
Neh4 and Neh5 domains mediates functions related to the transcription of Nrf2 target
genes [21,22]. Moreover, the Neh4 and Neh5 domains induce Nrf2 acetylation via interac-
tion with CREB binding protein (CBP) [23]. In contrast, the serine-rich region of the Neh6
domain negatively regulates Nrf2 half-life by a Keap1-independent mechanism. Specifi-
cally, the DSGIS and DSAPGS motifs of Neh6 are recognized by β-TrCP (β-transducing
repeat-containing protein), a protein involved in Nrf2 proteasomal degradation [24]. The
Neh7 domain plays a role in the repression of Nrf2 transcriptional activity through a
physical association with the retinoid X receptor α (RXRα). RXRα inhibits the binding
of CBP to the Neh4 and Neh5 domains, resulting in decreased expression of Nrf2 target
genes [25].
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Neh3, Neh4, and Neh5 domains are necessary for transactivation. Neh7 is necessary for binding with the RXRα. 
Several compounds specifically activate Nrf2. Nrf2 inducers may be classified into 
electrophilic and non-electrophilic. Electrophilic compounds interact strongly with cyste-
ine residues of Keap1, promoting conformational changes of this inhibitor that inhibit 
Nrf2 uniquitination. This is the case of bardoxolone [28,29], sulforaphane [30], dimethyl 
fumarate [31], and tert-butylhydroquinone [32,33], among others. Although non-electro-
philic compounds also inhibit the Nrf2-Keap1 interaction, their use in preclinical experi-
mental models has been less studied as compared with electrophilic ones. 
3. Regulation of the Nrf2 Pathway 
The regulation of Nrf2 activation status is complex and multifactorial because many 
injurious triggers, such as oxidative stress, activate this transcription factor and diverse 
cellular processes determine its expression (Figure 2). Although the main form of regula-
tion of the Nrf2 pathway is the aforementioned modification of Keap1 cysteines, there are 
other forms of regulation of this pathway at the transcriptional, post-transcriptional, 
translational, and post-translational level: 
3.1. Transcriptional Regulation 
Several transcription factors regulate the expression of the NFE2L2 gene that encodes 
Nrf2. The transcription factor aryl hydrocarbon receptor (AhR) recognizes XRE (xenobi-
otic response element) sequences at the NFE2L2 promoter and induces Nrf2 transcription 
[34]. Hence, AhR ligands, such as certain uremic toxins (e.g., indoxyl-sulfate) and xenobi-
otics upregulate Nrf2 expression. In the mouse, the nfe2l2 promoter also contains ARE 
sequences, to which Nrf2 may bind, providing a positive feedback loop to amplify Nrf2 
effects [35]. NF-κB, c-Jun, and c-Fos activate NFE2L2 transcription, mediating the increase 
in Nrf2 expression in response to inflammatory stimuli [36]. Components of the Notch 
signaling pathway [37], PI3K/Akt pathway [38], or oncogenic factors (Kras, B-Raf, and 
Figure 1. Schematic structure of Nrf2. Nrf2 has seven highly conserved domains (Neh1-Neh7). Among these domains,
Neh2 is the Keap1-binding domain. Neh6 is important for binding to the negative regulator β-TrCP. Both Neh2 and Neh5
are responsible for Nrf2 ubiquitination and degradation. Neh1 contains a cap‘n’collar basic-region leucine zipper domain
that is important for interacting with sMAF proteins and DNA, and is also required for the nuclear translocation of Nrf2.
Neh3, Neh4, and Neh5 domains are necessary for transactivation. Neh7 is necessary for binding with the RXRα.
The intracellular concentration of Nrf2 is determined by a complex equilibrium be-
tween its synthesis and its proteasomal degradation [15]. Under unstressed conditions,
Nrf2 is bound to its repressor Keap1. The main function of this repressor is to act as an
adaptor protein for the Cullin3 (Cul3)/Rbx1 (Ring box-1)-based E3-ubiquitin ligase, which
is responsible for the continuous ubiquitination and subsequent degradation of Nrf2 by
the proteasome [26]. Under physiological conditions, the half-life of Nrf2 is 10–30 min and,
in consequence, Keap1-mediated Nrf2 degradation keeps Nrf2 levels very low. However,
under oxidative stress conditions, Keap1 is oxidized at specific cysteine residues, promot-
ing conformational changes in this protein that inhibit the Keap1-mediated ubiquitination
of Nrf2. Nrf2 then translocates into the nucleus, where it regulates the expression of more
than 250 genes hat encode proteins involved in u tiple processes maintain cellular
home stasis [27].
Seve al compounds specifically activate Nrf2. Nrf2 inducers may be classified into
electrop ilic and non-electrophilic. Electrophilic compounds interact strongly with cystein
residues of Keap1, promoting conformational changes of this inhibitor hat inhibi Nrf2
uniqui nation. This is the c se of bardoxolone [28,29], sulforaphane [30], dimethyl fu-
marate [31], and tert-butylhydroquinone [32,33], among others. Although non-electrophilic
compounds also inhibit the Nrf2-Keap1 interaction, their use in preclinical experimental
models has been less studied as compared with electrophilic ones.
3. Regulation of the Nrf2 Pathway
The regulation of Nrf2 activation status is complex and multifactorial because many
injurious triggers, such as oxidative stress, activate this transcription factor and diverse
cellular processes determine its expression (Figure 2). Although the main form of regulation
of the Nrf2 pathway is the aforementioned modification of Keap1 cysteines, there are other
forms of regulation of this pathway at the transcriptional, post-transcriptional, translational,
and post-translational level:
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somal entry site (IRES) that can initiate/inhibit Nrf2 mRNA translation. (D) Nrf2 may be also regulated by Keap1-, β-TrCP- 
and Hrd1-mediated Nrf2 proteasomal degradation. 
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and iron homeostasis. 
Glutathione (GSH) is an electrophile-neutralizing molecule that scavenges ROS (hy-
drogen peroxide, hydroxyl radical, superoxide anion), reactive nitrogen species (RNS), 
and other toxic molecules [83]. GSH also plays a key role in redox signaling, xenobiotic 
Figure 2. Regulation of Nrf2 signaling. Nrf2 pathway is regulated at different levels: (A) transcriptional mechanism to
induce a positive regulation through binding to XRE or ARE in the NFE2L2 gene promoter region. NF-κB, c-Jun, and c-Fos
can regulate negatively NFE2L2 transcription. (B) NFE2L2 is also regulated in an epigenetic or post-transcriptional manner
including DNA methylation, histone modification, and microRNAs. miRNAs can induce Keap1 mRNA degradation or
Nrf2 mRNA inactivation/stabilization. (C) Nrf2 is also regulated at the translational level through an internal ribosomal
entry site (IRES) that can initiate/inhibit Nrf2 mRNA translation. (D) Nrf2 may be also regulated by Keap1-, β-TrCP- and
Hrd1-mediated Nrf2 proteasomal degradation.
3.1. Transcriptional Regulation
Several transcription factors regulate the expression of the NFE2L2 gene that encodes
Nrf2. The transcription factor aryl hydrocarbon receptor (AhR) recognizes XRE (xenobiotic
response element) sequences at the NFE2L2 promoter and induces Nrf2 transcription [34].
Hence, AhR ligands, such as certain uremic toxins (e.g., indoxyl-sulfate) and xenobiotics
upregulate Nrf2 expression. In the mouse, the nfe2l2 promoter also contains ARE sequences,
to which Nrf2 may bind, providing a positive feedback loop to amplify Nrf2 effects [35].
NF-κB, c-Jun, and c-Fos activate NFE2L2 transcription, mediating the increase in N f2
expression in response to inflamm tory stimuli [36]. Components of the Notch signaling
p thway [37], PI3K/Akt pathway [38], or oncogenic fac ors (Kras, B-Raf, and Myc) [39]
also duce NFE2L2 transcription. Recent evidence indicates that the tumor sup or p53
inhibits Nrf2-depend nt transcriptio of antioxidant ge es [40]. Moreover, the interaction
of RXRα with Nrf2 reduced the bindi g capa ity of Nrf2 to ARE regio s, diminishing
Nrf2-mediated antioxidant gene xpression [41]. Mo ifications in the XRE promoter,
inclu in ex c rbated methylation or single nucleotide polymorphisms (SNPs), e reased
NFE2L2 gene xpression in lung damage [42,43]. Interestingly, analysis of genome-wide
association studies (GWAS) has identified SNPs at the NFE2L2 lo us associated with
changes at estimated glomerular filtration rate (eGFR), a marker of CKD development
(Table 1) [44–46]. Finally, Nrf2 can promote Keap1 gene expression [47]. This auto-regulatory
negative loop could prevent excessive activation of Nrf2.
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Table 1. Genome-wide significant evidence of the Nrf2-eGFR association.
Variant and
Risk Allele Location Gene RAF
Reported
Trait Effect (β) CI p-Value
Study
Accession
rs35284526-A 2:177256796 NFE2L2 0.323 eGFR 0.0029 unit increase 0.0023–0.0035 1 × 10−26 GCST008058
rs34468415-A 2:177260414 NFE2L2 0.643 eGFR 0.0028 unit decrease 0.002–0.0036 1 × 10−24 GCST008059
rs12471433-A 2:177257637 NFE2L2 0.618 eGFR 0.0025 unit increase 0.0019–0.0031 2 × 10−14 GCST008747
rs17581525-G 2:177281634 NFE2L2 0.188 eGFR 6.541 z score increase NR 6 × 10−11 GCST007876
rs6433657-A 2:177269949 NFE2L2 0.469 eGFR 0.0023 unit increase 0.0017–0.0029 4 × 10−11 GCST008747
rs35955110-C 2:177278643 NFE2L2 0.435 eGFR 0.35 mL/min/1.73 m2 decrease 0.16–0.55 4 × 10−9 GCST007344
rs12471433-A 2:177257637 NFE2L2 0.702 eGFR 0.367 unit increase 0.25–0.48 2 × 10−10 GCST008745
Abbreviations: CI: Confidence interval, eGFR: estimated glomerular filtration rate, RAF: Risk allele frequency, N.R.: not reported.
3.2. Keap1-Independent Post-Translational Regulation
Besides Keap1, several proteins are involved in Nrf2 degradation. This fact is sup-
ported by studies in Nrf2 mutants lacking Keap1-binding regions, where Nrf2 degradation
was observed [36].
3.2.1. β-TrCP-Dependent Pathway
One of the mechanisms involved in Nrf2 post-translational regulation is mediated by
glycogen synthase kinase-3beta (GSK-3β). GSK-3β phosphorylates the Nrf2 DSGIS motif,
which is further recognized by β-TrCP. β-TrCP is an adaptor for the Skp1-Cul1-Rbx1-F-box
protein (SCF) E3 ubiquitin ligase complex, involved in Nrf2 ubiquitination and degradation
by the proteasome [48]. Therefore, Nrf2 phosphorylation by GSK-3β allows Nrf2 to be
recognized by β-TrCP thus facilitating subsequent Nrf2 degradation [24,48]. Moreover,
GSK-3β modulates additional Nrf2 regulators. Specifically, GSK-3β phosphorylates the
proto-oncogene product Fyn, a tyrosine kinase, leading to its accumulation in the nucleus,
and promoting further Nrf2 nuclear exportation and degradation [49]. Other kinases, such
as extracellular signal-regulated kinase (ERK), C-Jun N-terminal kinase (JNK), PKR-like
endoplasmic reticulum kinase (PERK), phosphatidylinositol 3-kinase (PI3K), and protein
kinase C (PKC) inhibit GSK-3β and promote nuclear import of Nrf2 [50]. In contrast, p38
mitogen-activated protein kinase (p38) phosphorylation induces Nrf2 degradation in the
cytoplasm [51].
3.2.2. Hrd1-Dependent Pathway
Nrf2 degradation may be also mediated by the E3 ubiquitin ligase Hrd1 (also called
SYVN1). Hrd1 induces Nrf2 ubiquitination and proteasomal degradation, acting as a
negative regulator [52]. It has been proposed that Nrf2 interacts with the C-terminal domain
of Hdr1 through its Neh4 and Neh5 domains, which induces Nrf2 ubiquitination and
subsequent degradation, independent of Keap1 and β-TrCP. Pharmacological inhibition of
Hdr1 (treatment with LS-102) or deletion of its gene prevented Nrf2 loss [52]. Currently,
there are no studies about the role of Hrd1 on Nrf2 modulation specifically in the kidney;
however, recent studies in other pathologies such as liver damage suggest that the inhibition
of Hdr1 could be also a promising therapeutic target against renal injury.
3.3. Translational Regulation
An internal ribosomal entry site (IRES) at the 5′ untranslated region (UTR) of the Nrf2
mRNA is needed to initiate its internalization into ribosomes for protein synthesis. Like-
wise, an inhibitory element exists upstream of the IRES, blocking ribosomal internalization
of Nrf2 mRNA. Nrf2 translation also seems to be controlled by the cellular redox state [53].
Specifically, ROS increase Nrf2 translation in an IRES-dependent manner by promoting
the entry of the mRNA into ribosomes [54]. Thus, Nrf2 translation efficiency is low under
basal conditions and markedly increased under oxidative stress situations.
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3.4. Post-Transcriptional or Epigenetic Regulation
Recent studies show that Keap1/Nrf2 signaling may be regulated by epigenetic mecha-
nisms, including DNA methylation, histone modification, and microRNAs. A large number
of microRNAs regulate Nrf2 activity and availability [55]. miR-144 has been described as a
negative modulator of Nrf2 in immature red blood cells of patients with homozygous sickle
cell disease [56]. The direct binding of miR-144 to the UTR of Nrf2 mRNA decreases Nrf2
in K562 lymphoblasts and primary erythroid progenitor cells [55]. miR-144 also has been
associated with Nrf2 modulation in retinal [57], alveolar [58] or neuronal damage [59]. An-
other study showed that miR-200a interacts with the 3′-UTR of Keap1 mRNA, favoring its
degradation and thereby promoting Nrf2 nuclear translocation and activation [60]. miR-93
and miR-28 decreased Nrf2 levels and the expression of antioxidant proteins [61,62]. miR-
27a, miR-142-5p and miR-153 repress Nrf2 mRNA in neuronal cells [63]. Under hypoxic
conditions, miR-101 stabilized Nrf2 by targeting Cul3 and induced the expression of Nrf2-
target genes [64]. In cisplatin-induced AKI, miR-140-5p interacts with the 3′-UTR of Nrf2
mRNA and increased Nrf2 expression, with consequent improvement of renal damage [65].
Another study showed that miR-125b was transactivated by Nrf2 and inhibited the AhR
repressor, protecting the kidney from cisplatin-induced AKI [66]. In renal proximal tubular
epithelial cells, the toxic effects induced by ochratoxin A were restored after blockade of
miR-132 and miR-200c with antagomiRs, resulting in increased Nrf2 expression [67]. In
colistin-induced nephrotoxicity, miR-873-5p decreased Keap1 expression, with consequent
increase of Nrf2 protein expression [68].
Recent results have demonstrated that histones 3 (H3) and 4 (H4) are closely related to
epigenetic regulation of Nrf2 [69,70]. The acetylation of Lys-16 and Lys-588 in H4 induced
the expression of Nrf2-related genes [71]. In microglia, lipopolysaccharide (LPS) treatment
activated histone deacetylase (HDAC), resulting in diminished H3 and H4 acetylation
and decreased levels of Nrf2 [72]. Moreover, the p300/CBP histone acetyltransferase di-
rectly acetylated Nrf2, increasing Nrf2 promoter-specific DNA binding in arsenite-induced
oxidative stress [73]. Finally, a study in prostate cancer cells suggested that hypermethy-
lated CpG islands are closely related to histones modification and the modulation of Nrf2
transcription activity [74].
In cancer, alternative Nrf2 pathway activation has also been associated with abnormal
transcript variants from the NFE2L2 gene. These alternative splicing products have been
described in solid tumors and lack exon 2, or exons 2 and 3 [75]. These aberrant Nrf2
variants are devoid of the Keap1 interaction domain, resulting in constitutive induction of
the Nrf2 signaling pathway [75]. Currently, there are no data about the role of epigenetic
modification of Nrf2 in the progression of renal damage. Therefore, further studies are
warranted to address this issue.
4. Nrf2 and Cellular Homeostasis
Nrf2 is a key regulator of genes associated with the antioxidant response [76], bio-
transformation of endobiotics and xenobiotics [53], lipid and carbohydrate metabolism [15],
cellular iron homeostasis [77], autophagy [78], and inflammation [79], which are all pro-
cesses that are involved in the maintenance of cellular homeostasis.
4.1. Nrf2 in Redox Homeostasis and Detoxifying Processes
An increase in cellular ROS production disrupts redox homeostasis and alters normal
cellular processes [80]. To limit these harmful effects, cells induce the expression of several
cytoprotective genes, mainly regulated by AREs in their upstream regions [81]. Numer-
ous transcriptions factors are regulated by changes in the intracellular redox conditions,
including Nrf2 [16]. The Nrf2-mediated antioxidant response regulates the expression
of genes encoding proteins involved in the detoxification and elimination of pro-oxidant
compounds by conjugation reactions and by increasing cellular antioxidant capacity (e.g.,
heme oxygenase 1 (HO-1), catalase (CAT), superoxide dismutase (SOD), and NAD(P)H
dehydrogenase quinone 1 (NQO-1)) [82]. These proteins can scavenge free radicals directly
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or indirectly, thereby reducing cellular oxidative stress. Moreover, Nrf2 is a key regula-
tor of the glutathione and thioredoxin systems, NADPH production and utilization, and
iron homeostasis.
Glutathione (GSH) is an electrophile-neutralizing molecule that scavenges ROS (hy-
drogen peroxide, hydroxyl radical, superoxide anion), reactive nitrogen species (RNS),
and other toxic molecules [83]. GSH also plays a key role in redox signaling, xenobiotic
detoxification, and regulation of cell proliferation, apoptosis, immune response, and fi-
brogenesis [84]. Nrf2 regulates the expression of genes encoding essential enzymes for
the synthesis of GSH, such as the glutamate-cysteine ligase (GCL) enzyme complex [16].
Additionally, Nrf2 controls the amount of intracellular cysteine, a limiting substrate in
GSH synthesis [85], by regulating the expression of genes encoding the cystine/glutamate
transporter xCT [86]. Nrf2 also modulates GSH utilization, as it controls the expression of
detoxifying and antioxidant defense enzymes, such as glutathione peroxidase 2 (GPX2)
and glutathione-S-transferases (GSTs) [85]. GPX2 or GSTs catalyze the reduction of ROS
by transforming GSH into its oxidized form (GSSG). GSH is then regenerated from GSSG
through the Nrf2-regulated enzyme glutathione reductase (GSR) and the reducing agent
NADPH [83].
Nrf2 modulates thioredoxin (Trx) gene expression [85]. Trx is an antioxidant protein
of the so-called Trx system, which also includes the enzyme thioredoxin reductase (TrxR),
the NADPH cofactor, and Trx regulatory proteins. TrxR, using NADPH, reduces oxidized
Trx to its active form. Active Trx is then able to cleave disulfide bridges by transferring
electrons from its reactive thiol groups [87]. Additionally, reduced Trx can be used by
peroxiredoxins (Prx), another class of antioxidant enzymes, to reduce intracellular levels of
hydrogen peroxide (H2O2) [88].
Nrf2 induces the production of the reducing agent NADPH, a critical cofactor in the
glutathione and Trx reductase systems [89,90]. NADPH production is mediated by the
expression of four enzymes regulated by Nrf2 (glucose-6-phosphate dehydrogenase, 6 phos-
phogluconate dehydrogenase, malic enzyme 1, and isocitrate dehydrogenase 1) [38,91,92].
Free heme promotes oxidation of proteins, DNA, and lipids [93] and disturbs cy-
toskeletal integrity [77,94]. Therefore, the degradation of free heme is essential to protect
against oxidative stress. Nrf2 modulates the expression of HO-1 [95], a cytoprotective en-
zyme that degrades heme and generates equimolar amounts of the antioxidants biliverdin
and CO [95]. Nrf2 also modulates the expression of ferritin, a protein that allows the safe
accumulation of iron in the cell, avoiding iron-related oxidative stress [89].
4.2. Nrf2 and Inflammation
Uncontrolled inflammatory responses contribute to a wide variety of pathologies,
including renal disease [96]. Recent studies suggest that Nrf2 may protect against inflam-
mation, beyond its antioxidant activity [53]. Nrf2 is essential in the regulation of the innate
immune response, reducing the expression of pro-inflammatory genes, and enhancing
anti-inflammatory signaling [97]. Nrf2 activation prevents LPS-induced transcriptional
upregulation of pro-inflammatory cytokines, such as IL-6 and IL-1β, in macrophages [98],
and TNF-α, IL-6, and other chemokines (CCL2 and CXCL2) in neutrophils [53]. Nrf2
inhibits the transcription of the genes encoding these cytokines by its binding to their
promoter regions and suppressing the attachment of RNA polymerase II to DNA [98].
The transcription factor NF-κB is a master driver of the inflammatory response. Cell
exposure to inflammatory stimuli, such as LPS, IL-1β, H2O2 or TNF-α, results in the protea-
somal degradation of IκB protein, allowing the nuclear translocation of NF-κB. Activated
NF-κB induces the expression of pro-inflammatory cytokines, chemokines, and adhesion
molecules [53]. It is currently considered that Nrf2 activation status influences the NF-κB
signaling pathway through three different mechanisms [79]. First, Keap1 promotes the
ubiquitination and degradation of the upstream kinase IKKβ, resulting in the inhibition
of NF-κB activation [99]. Second, reduced oxidative stress further decreases IKKβ activa-
tion [100]. Third, Nrf2 competes with NF-κB for binding to the transcriptional coactivator
Antioxidants 2021, 10, 39 8 of 31
CBP, which is required by both transcription factors, thus reducing the expression of NF-
κB-modulated genes [101]. Finally, in vivo studies have confirmed that Nrf2 negatively
regulates NF-κB transcriptional activity [102]. The anti-inflammatory effects of Nrf2 may
be also related to its inhibitory role in NLRP3 (NLR family pyrin domain containing 3)
inflammasome activation [103,104].
4.3. Nrf2 and Autophagy
Autophagy is a mechanism by which cells remove damaged organelles and misfolded
proteins. Autophagy contributes to preserving cellular homeostasis and acts as a defense
mechanism against oxidative stress. The autophagy adaptor p62 and Keap1 play key roles
in the crosstalk between autophagy and the Nrf2 axis [78]. Nrf2 modulates the expression
of the sequestosome 1 (SQSTM1) gene, which encodes the p62 protein [16]. p62 interacts
with ubiquitination targets via its ubiquitin association domain (UBA), allowing their
recruitment to the autophagosome through the Microtubule-associated protein 1A/1B-
light chain 3 (LC3)-interacting motif. p62 interacts with the Nrf2 binding domain of Keap1,
resulting in Keap1 degradation in autophagosomes [105]. Furthermore, Nrf2 regulates the
transcription of NDP52 (nuclear dot protein 52), a protein that recognizes ubiquitinated
proteins and directs them to lysosomes for degradation [106]. Nrf2 controls the expression
of genes involved in autophagy initiation (ULK1, Unc-51-like autophagy-activating kinase)
and autophagosome formation (ATG4D (Autophagy-Related 4D Cysteine Peptidase), ATG7
(Autophagy-Related 7), GABARAPL1 (Gamma-aminobutyric acid receptor-associated
protein-like 1) [107]. Moreover, oxidized intracellular proteins can be degraded through
a selective type of autophagy, the so-called chaperone-mediated autophagy (CMA). A
key element in CMA is lysosomal-associated membrane protein 2A (LAMP2A). LAMP2A
recognizes complexes formed by degradation-targeted proteins and HSPA8/HSC70 (heat
shock protein family A (Hsp70) member 8), promoting their lysosomal internalization and
degradation [108]. Data from multiple studies have pointed to the role of Nrf2 in CMA due
to the presence of ARE sequences in the promoter of the LAMP2A gene [108,109].
5. Nrf2 and AKI
AKI refers to a sudden decrease in renal function. AKI is produced by various causes:
sepsis, ischemia-reperfusion (I/R), rhabdomyolysis, massive intravascular hemolysis, pres-
ence of heavy metals (cadmium, chromium, or arsenic), food additives (potassium bromate),
mycotoxins, contrast liquid, cancer chemotherapeutic agents or therapeutic molecules such
as immunosuppressants (Cyclosporin A), etc. [110]. AKI is characterized by increased
oxidative stress, mitochondrial dysfunction, and inflammation. In this sense, Nrf2-based
therapies may be protective against renal damage associated with AKI (Table 2) [111–113].
Table 2. Beneficial effects of Nrf2 inducers in experimental AKI.
AKI Model Compound Beneficial Effects
I/R
Curcumin Reduces urea and cystatin C plasma levels. Decreases renalhistological damage, cell death, and ROS.
Bardoxolone
Ameliorates renal function. Decreases tubular injury, inflammation
and oxidative stress. Increases renal GSH levels, upregulates GCL,
NQO-1, and HO-1 expression.
Resveratrol Improves renal function, decreases oxidative stress, cell death, andinflammation by decreasing TLR4/NF-κB signaling.
RTA-408 Improves renal function and histological damage. Increases GSHlevels and GCL expression.
Tert-butylhydroquinone Reduces oxidative and nitrosative stress. Ameliorates renaldysfunction and reduces cell death by activating HO-1.
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Table 2. Cont.
AKI Model Compound Beneficial Effects
Extendin-4 Decreases renal injury, oxidative stress and inflammation byupregulating NQO-1 and SOD expression.
Sulforaphane
Decreases histological damage, ROS production, inflammation, cell
death and GSK3-β activation. Enhances HO-1 and
NQO-1 expression.
Aristolochic acid (AA) Bardoxolone Decreases histopathological renal damage, improves renal function,and increases Nrf2, NQO-1, and HO-1 expression.
Pigment nephropathy
Curcumin
Improves renal function, decreases histological damage, reduces
tubular injury, oxidative stress, inflammation, and cell death by
increasing HO-1 expression.
Sulforaphane Improves renal function, limits histological damage and decreasespodocyte and tubular injury, inflammation and oxidative stress.
Agmatine Improves renal function. Decreases TNF-α and IL-1β production andNF-κB activation.
Sepsis
Dexmedetomidine Improves renal function and ameliorates kidney injury by increasingGSK-3β/Nrf2 pathway
LBP Improves renal function and limits histological damage. ReducesROS and increases HO-1 and NQO-1 levels.
Polydatin
Improves renal function, reduces TNF-α, IL-1β, and IL-6 production,
Myeloperoxidase activity, and MDA content. Decreases NF-κB
activation and increases Nrf2 and HO-1 expression.
Alpinetin
Decreases blood urea nitrogen (BUN) and creatinine levels. Reduces
ROS, MDA, and TNF-α, IL-6, and IL-1β production. Inhibits TLR4
expression and NF-κB activation.
Mangiferin
Attenuates renal dysfunction and reduces oxidative stress and IL-1β
and IL-18 serum levels. Reduces tubular cells death and suppresses
renal NLRP3 activation.
Pachymic acid Reduces histological renal damage. Inhibits renal TNF-α and IL-6levels. Decreases iNOS expression.
Cisplatin
Sulforaphane
Ameliorates renal function. Reduces renal structural damage and
oxidative/nitrosative stress. Increases catalase, glutathione
peroxidase, and glutathione-S-transferase expression.
Sodium polysulfide Reduces creatinine levels. Decreases NADPH oxidase activation andinduces Nrf2 nuclear translocation.
Baicalein
Ameliorates kidney injury and function. Reduces oxidative stress,
cell death, and inflammation (iNOS, TNF-α, and IL-6 expression and
MAPKs and NF-κB activation).
Astragaloside IV
Ameliorates renal dysfunction and histopathological injury.
Increases SOD, GPX, and CAT activity. Reduces MDA, TNF-α, and
IL-1β production.
DMF Decreases BUN and tubular injury. Reduces fibrosis byincreasing NQO-1.
Heavy metal toxicity Curcumin Attenuates renal dysfunction and histological damage. Reducesmitochondrial dysfunction and increases GSH levels.
Gentamicin Curcumin Decreases BUN and creatinine. Reduces ROS and lipid peroxidationand increases GSH content and GPX, GST, SOD, and CAT activity.
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5.1. Role of Nrf2 in AKI-Associated Oxidative Stress
ROS, such as hydroxyl radical (HO•) and superoxide anion (O2•−) free radicals, and
the non-radical oxidants H2O2, hypochlorous acid (HOCl), and peroxynitrite (ONOO−)
induce renal damage during AKI [114–116]. One of the most important free radicals
involved in the pathophysiology of AKI is O2•−, which is produced by dysfunctional
mitochondria [117]. O2•− can interact with other radicals including •NO to form reactive
nitrogen species, such as ONOO−, that contribute to AKI progression [118]. ROS produced
during AKI induce DNA damage, and modify proteins and lipids, modifying their structure
and function [119]. In ischemic renal injury, •NO, O2•−, and/or ONOO− take part in the
renal oxidative injury [120,121]. In sepsis-mediated AKI, recruited inflammatory cells to
produce O2•− via NADPH oxidase, and HOCl from H2O2 or xanthine oxidase (XO) [117].
During the septic process, there is also intense renal vasoconstriction and endothelial cell
injury associated with higher •NO and ONOO− levels [122]. In rhabdomyolysis-induced
AKI, HO• is produced by ferric/ferryl heme groups that promote lipid peroxidation and
further renal damage [123].
Several studies have reported increased expression of Nrf2-regulated antioxidant
genes in experimental I/R-induced AKI, whereas no induction of these protective genes
was observed in Nrf2 knockout mice, suggesting a defensive role of Nrf2 against I/R-
mediated renal damage [124,125]. Nrf2 knockout mice had a higher loss of renal func-
tion, oxidative stress, and apoptosis than wild-type mice in an experimental model of
I/R-associated AKI. These I/R harmful effects were not observed in Keap1 knockdown
mice [126]. Anti-oxidant strategies with the Nrf2 inducers bardoxolone or sulforaphane
reduced renal damage during the acute phase of I/R-AKI [127,128]. Moreover, curcumin
decreased serum urea and cystatin C concentration and reduced malondialdehyde (MDA)
levels [129], whereas bardoxolone increased Nrf2, and HO-1 expression [127]. Activation
of Nrf2 with the synthetic compound RTA dh404 (triterpenoid 2-cyano-3,12-dioxoolean-
1,9-dien-28-oic acid) during the initial phase of I/R decreased tubular injury in subsequent
phases by increasing GSH and NADPH production [126]. Experimental studies with the
Nrf2 inducer RTA-408 (oleanane triterpenoid compound) improved I/R-associated injury
by inducing Nrf2 activation and expression of downstream antioxidant genes [130,131]. Hy-
perglycemia aggravates renal injury caused by I/R. Treatment with tert-butylhydroquinone
(TBHQ) reduced I/R-related injury during diabetes via Nrf2 activation, reducing cell death
and oxidative stress [132]. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist
used in the treatment of diabetes, also activates Nrf2 leading to an increase in antioxidant
and anti-inflammatory defenses. Exendin-4 decreased renal injury in I/R and upregulated
antioxidant mediators such as NQO-1, Nrf2, and SOD [133]. Simvastatin, a 3-hydroxy-3-
methyl-glutaryl-coenzyme A reductase inhibitor, also protected from I/R kidney damage,
activated Nrf2, and increased HO-1 levels [134].
Activation of Nrf2 was also useful against renal toxicity induced by heavy metals such
as chromium [135], arsenic [136], and cadmium [137]. A study in rat kidney epithelial cells
showed that downregulation of Nrf2 expression using specific siRNAs decreased HO-1 and
GCL levels, leading to an increase in cadmium-induced oxidative stress [137]. Conversely,
Nrf2 activation decreased the renal levels of NADPH oxidase and inducible nitric oxide
synthase (iNOS) in an experimental model of sodium arsenite nephrotoxicity in rats [136].
Moreover, the Nrf2 inducer curcumin improved the nephrotoxic effect of chromium and
attenuated mitochondrial dysfunction via restoration of the antioxidant response, nuclear
Nrf2 translocation, and increased GST activity [135]. Bardoxolone improved aristolochic
acid-induced nephrotoxicity by decreasing the expression of Keap1 and, consequently,
increasing the expression of Nrf2, NQO-1, and HO-1 [138].
Sepsis is one of the factors that trigger AKI in intensive care patients [139] and the
pathogenic endotoxin LPS is the most important factor responsible for its occurrence [140].
LPS has been described both as a ROS producer and a blocking agent of the antioxidant
response that finally leads to AKI, downregulating the production of CAT, SOD, and
GSH as well as the Nrf2 signaling pathway [141,142]. In a model of LPS-induced AKI,
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treatment with dexmedetomidine, a selective α2 adrenal receptor (α2-AR) agonist, induced
the expression of HO-1 and NQO-1 via the GSK-3β/Nrf2 signaling pathway, decreasing
AKI pathological features [141,143]. A recent report determined that Lycium barbarum
polysaccharide (LBP) also induces Nrf2 activation, upregulating the antioxidant response,
and this protective effect was reversed by brusatol (an inhibitor of Nrf2 signaling) [144].
The natural precursor and glycoside form of resveratrol, polydatin, improved LPS-induced
AKI by increasing Nrf2 and HO-1 expression [145].
Nrf2 deficient mice showed increased renal damage and a lower survival rate in
cisplatin-induced AKI, suggesting a key protective role of Nrf2 in this pathological set-
ting [146]. Thus, Nrf2 activation protects from cisplatin nephrotoxicity. Nrf2 inducers, in-
cluding bardoxolone [147] and sulforaphane [148], were protective in cisplatin-induced AKI.
Sodium polysulfide induced nuclear translocation of Nrf2 and protected from cisplatin-
induced renal injury by decreasing NADPH oxidase activation [149]. Similar protective
results against the nephrotoxic damage of cisplatin were observed with other molecules
and herbal natural extracts [150–155].
Nfe2l2 gene deletion has a deleterious effect on renal cell viability after incubation with
the immunosuppressant Cyclosporin A (CsA), a compound that may induce AKI [156].
Treatment with the Nrf2 inducer sulforaphane ameliorated AKI induced by CsA [156].
Moreover, the mycotoxin ochratoxin A (OTA) has been described to be able to induce
AKI [67,157]. Overexpression of Nrf2 in renal tubular cells using adenoviral vectors
inhibited oxidative stress and TGF-β signaling activation induced by OTA [67].
In pigment nephropathy, sulforaphane protects from intravascular hemolysis in mice,
preserving renal function and decreasing oxidative stress, inflammation, and tubular and
podocyte injury [158,159]. Curcumin also preserved renal function and decreased renal
inflammation, oxidative stress, and cell death in rhabdomyolysis-induced AKI, and it
protected cultured tubular cells against myoglobin toxicity through the activation of the
Nrf2 signaling pathway [160–162]. The use of sulforaphane reduced ROS production and
restored histological and cytotoxic damage in myoglobin-induced AKI [163].
5.2. Nrf2 in AKI-Related Inflammation
Inflammation is a key contributor to AKI that may be regulated by Nrf2. In I/R-
related AKI, resveratrol-mediated Nrf2 induction reduced oxidative stress, cell death, and
inflammation by decreasing Toll-like receptor 4 (TLR4)/NF-κB pathway activation [164].
Recent evidence described that T lymphocytes are key mediators of I/R-AKI [165,166].
Specific deletion of Keap1 in T lymphocytes (CD4-Keap1-KO mice) increased the expression
of antioxidant response-related genes (NQO-1, HO-1, and GCL, reduced the production of
inflammatory cytokines (TNF-α, IFN-γ, and IL-17), and improved renal function [167].
In cisplatin-induced nephropathy, treatment with the flavonoid baicalein decreased
renal injury and downregulated the activation of MAPKs and NF-κB by inducing Nrf2
nuclear translocation [168]. Interestingly, in experimental models of cisplatin-associated
AKI and cultured tubular cells, inhibition of inflammatory response by the antioxidant
Astragaloside IV was abrogated in Nrf2 knockout mice [169]. In gentamicin-related AKI,
curcumin was demonstrated to decrease inflammation [170,171].
In an experimental model of intravascular hemolysis-induced AKI, dimethyl fumarate
(DMF) increased Nrf2 in the liver and reduced liver inflammation [172]. In experimental
rhabdomyolysis-induced AKI, the aminoguanidine agmatine activated Nrf2 and reduced
renal inflammation, decreasing TNF-α, IL-1β, and NF-κB [173].
Sepsis-induced AKI involves a high inflammatory response [174]. Alpinetin, mangiferin,
and pachymic acid activated Nrf2 and protected against LPS- or cecal-ligation and puncture-
induced AKI, decreasing inflammatory cytokines such as TNF-α, IL-6, and IL-1β and/or
suppressing the activation of the NRLP3 inflammasome [175–177].
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5.3. Nrf2 Decreases Long-Term Fibrosis after AKI
Persistent inflammation over time promotes renal damage by transforming a regenera-
tive response into a pathological process [178]. Thus, renal fibrosis becomes a maladaptive
response characterized by the accumulation of extracellular matrix components, mainly
fibronectin and collagens (I, III, and IV) [179,180]. Oxidative stress may contribute to
fibrosis by inducing the proliferation of activated fibroblasts, which are the main source of
extracellular matrix accumulation in the kidney [181,182]. Bardoxolone reduced fibrosis
through the Nrf2/Smad7 axis, inhibiting the TGF-β/Smad signaling, and ameliorating
aristolochic acid-induced AKI [183]. In cisplatin-AKI, DMF also reduced peritubular fi-
brosis [184]. In a mouse model of folic acid-induced AKI, specific deletion of GSK3β in
renal tubules or treatment with a GSK3β inhibitor improved the Nrf2 antioxidant response,
independently of Keap1, protecting from AKI to CKD transition [185].
6. Nrf2 in the Context of CKD
There is evidence that the Nrf2 signaling pathway protects against oxidative stress,
inflammation, and fibrosis in CKD (Table 3).
Table 3. Beneficial effects of Nrf2 inducers in CKD.
CKD Model Compound Beneficial Effect
DN
Curcumin
Decreases urine SOD and MDA levels, histological damage, inflammation, and
cell death by activating HO-1. Decreases NRLP3 activity, reduces IL-1β and
cleaved caspase 1 levels.
B066- curcumin Ameliorates renal function, decreases inflammation associated with JNK andNF-κB signaling.
C66- curcumin Prevents kidney fibrosis by increasing Nrf2 activation and decreases kidney injuryand JNK activity.
Resveratrol Reduces creatinine levels, oxidative stress, decreases TGF-β1 and fibronectinexpression and NF-κB/p65 activation.
Sulforaphane Decreases glomerular damage and fibrotic progress by increasing HO-1 andNQO-1 expression.
LN
Curcumin Increases Nrf2 activation and ameliorates renal function. Decreases IL-6, TNF-αand CCL2 levels.
Bardoxolone methyl Decreases proteinuria and serum BUN levels. Reduces the activity of theMEK-1/2, ERK, STAT3 signaling pathways.
Epigallocatechin-3-gallate Decreases serum creatinine and BUN levels. Reduces NRLP3, caspase-1, IL-1β,and IL-18 expression.
DMF Reduces proteinuria and inflammatory response by increasing HO-1 andNQO-1 expression.
Sulforaphane Ameliorates renal function. Modulates TGF-β1, fibronectin, and iNOS expression.
IgAN
Antroquinonol Ameliorates renal function and reduces renal lesions. Decreases NRLP3inflammasome pathway activity.
Osthole Reduces albuminuria and renal lesions. Reduces oxidative stress, inflammation byinhibiting NLRP3 and NF-κB signaling.
FSGS
THSG Decreases podocytes injury, fibrosis, and glomerulosclerosis. Reduces albuminuriaand lipid peroxidation by increasing HO-1 and NQO-1 expression.
Antroquinonol Decreases proteinuria, ROS production, inflammation, fibrosis, and podocytedamage by increasing HO-1 expression.
Osthole Improves proteinuria and histological damage. Decreases oxidative stress,inflammation and cell death by increasing HO-1 expression.
Citral Decreases inflammation, fibrosis, podocyte damage and proteinuria.
Astaxanthin Improves renal function and reduces glomerular and interstitial fibrosis,inflammation, and cell death by increasing HO-1 levels.
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Table 3. Cont.
CKD Model Compound Beneficial Effect
CGN Epigallocatechin-3-gallate Increases kidney function, PPARγ, and SIRT1 levels. Modulates p-AKT, p-JNK,p-ERK1/2, and p-P38 levels.
MN
Epigallocatechin-3-gallate Improves renal function and histological damage. Increases GSH levels and HO-1and NQO-1 expression.
Resveratrol Reduces proteinuria and glomerular lesions. Decreases oxidative stress, apoptosis,and inflammation. Increases HO-1 expression.
Melatonin Reduces proteinuria and glomerular lesions. Reduces oxidative stress, cell death,and inflammation by increasing HO-1 expression.
UUO
Epigallocatechin-3-gallate Ameliorates renal function. Decreases inflammation, ROS, and fibrosis byinhibiting NF-κB and increasing HO-1 expression.
Sinomenime Attenuates renal fibrosis, oxidative stress, inflammation, and fibrosis by inhibitingthe TGFβ/Smad and Wnt/β-catenin signaling pathways.
Sulforaphane Reduces tubular cell death and interstitial fibrosis.
DMF Attenuates renal fibrosis (α-SMA, fibronectin, and type 1 collagen expression) byinhibiting TGF-β/Smad3 signaling.
Subtotal
nephrectomy
Curcumin Reduces plasma creatinine levels, TNF-α production and NF-κB activation.
RTA dh404 Decreases renal damage, inflammation, oxidative stress and fibrosis by reducingNF-κB activation.
6.1. Nrf2 Protects from Oxidative Stress in CKD
Oxidative stress contributes to the pathogenesis and progression of CKD [186,187].
Studies in several experimental models of CKD, including subtotal nephrectomy, unilateral
ureteral obstruction (UUO), or adenine-induced tubulointerstitial injury reported increased
Keap1 expression and decreased Nrf2 nuclear translocation, leading to downregulation
of antioxidant enzymes [180–183,188–191]. A study in kidney biopsies from CKD patients
suggested that the Nrf2 signaling pathway may play a key role linking inflammation and
metabolism network in renal diseases via a transcriptional mechanism [192].
Diabetic nephropathy (DN) is a severe complication of diabetes mellitus and a frequent
cause of CKD [193]. Hyperglycemia induces mitochondrial ROS overproduction [194],
promoting glomerular and tubular damage [195]. In a model of experimental DN in rats,
renal Nrf2 expression was downregulated whereas Keap1 was upregulated [196], and
similar results were observed in type 2 diabetes patients [197]. In a model of nephropathy
in type 2 diabetic rats, curcumin increased Nrf2 and HO-1 protein levels, thereby reducing
ROS production (as assessed by urine SOD and MDA levels) [196]. In vitro and in vivo
studies have demonstrated that sulforaphane ameliorated nephropathy in diabetic rats
by activating the Keap1/Nrf2 signaling pathway, an effect that was abolished by siRNA
silencing of Nrf2 in cultured tubular cells [198]. The combination of resveratrol and
rosuvastatin restored Nrf2 renal expression and thereby decreased hyperglycemia-induced
oxidative damage [199].
Furthermore, patients with autoimmune kidney diseases, such as lupus nephri-
tis, showed enhanced oxidative stress (reflected in increased anti-8-Oxo-dG staining),
as well as Nrf2 activation with increased NQO-1 expression in tubular and glomerular
cells [200]. Crescentic glomerulonephritis (GN) is a glomerular disorder characterized
by the irreversible loss of podocytes, endothelial injury, and the generation of glomeru-
lar crescents [201,202]. Oxidative stress and inflammation contribute to kidney injury
in these pathological conditions [203]. In experimental crescentic GN, Nrf2 deficiency
aggravated glomeruli and podocyte injury, showing an elevated incidence of crescent for-
mation, necrotic lesions, podocyte foot process fusion, and glomerular basement membrane
thickening [204].
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IgA nephropathy (IgAN) is the most frequent form of glomerulonephritis [85]. Ox-
idative stress has been described as one of the main players in IgAN pathophysiology,
correlating with the disease progression [205]. In mice with progressive IgAN, antro-
quinonol, and osthole, induced the Nrf2 antioxidant signaling pathway and reduced
oxidative stress [206]. Oxidative stress has been also related to the progression of focal
segmental glomerulosclerosis (FSGS) [207]. Diverse Nrf2 activators (antroquinonol, osthole,
citral, or astaxanthin) were nephroprotective in experimental models of FSGS by reducing
ROS production, and increasing HO-1, GPX4, and Nrf2 activity [207–210]. In murine mem-
branous nephropathy, resveratrol or melatonin administration induced the expression of
Nrf2 target genes, such as HO-1 [211,212]. Besides, epigallocatechin-3-gallate restored Nrf2
and GSH levels in mice with anti-glomerular basement membrane glomerulonephritis,
increasing NQO-1 and HO-1 protein expression [213].
6.2. Nrf2 in the Inflammatory Response Associated with CKD
It is well known that inflammation is a key event in the progression of renal disease.
Since Nrf2 is involved in the regulation of the inflammatory response, several studies
have addressed the role of this transcription factor in the late stages of renal disease.
Remarkably, CKD patients in hemodialysis showed reduced Nrf2 expression and NF-κB
activation in peripheral blood mononuclear cells (PBMCs) [214,215]. In contrast, PBMCs
from CKD patients in peritoneal dialysis showed upregulated Nrf2 mRNA and protein
expression [216]. However, given the low number of patients included in these studies
and the lack of adjustment for comorbidities and medication, no robust conclusions can be
drawn from these reports.
In experimental models of CKD (subtotal nephrectomy), natural and synthetic Nrf2
inducers directly or indirectly decreased renal inflammation. Indeed, curcumin increased
the expression of Nrf2 and HO-1 and decreased NF-κB activation and subsequent produc-
tion of the proinflammatory cytokine TNF-α, and it also reduced the interstitial infiltration
of immune cells [217,218]. In the same experimental model, the synthetic compound RTA
dh404 modulated Nrf2-mediated antioxidant responses and decreased NF-κB activation
and renal damage [219], and it also restored endothelial function [220]. Studies with other
antioxidant molecules that induced Nrf2 signaling (epigallocatechin-3-gallate and sinome-
nine) also reported anti-inflammatory effects in the UUO model, a popular model of CKD
associated with progressive renal fibrosis [221,222].
Inflammation is also involved in the occurrence and progression of DN. In diabetic
mice, the Nrf2 inducer curcumin decreased NLRP3 inflammasome activity, as reported
by reduced protein levels of IL-1β, cleaved caspase-1, and NLRP3 [223]. A novel cur-
cumin derivative (B066) also reduced macrophage infiltration in DN mice by inhibiting
c-Jun N-terminal kinase/NF-κB activation [224,225]. Further, a decreased inflammatory
response was reported after the induction of Nrf2 by sulforaphane in experimental type
2 diabetes [226].
Lupus nephritis (LN) leads to glomerular inflammation and progressive loss of renal
function [227]. Nrf2 deficiency in experimental LN increased oxidative stress and renal
inflammation [200]. Moreover, Nrf2-deficient mice with experimental lupus-like nephritis
displayed lower glomerular filtration rate (GFR) and severe glomerular damage, as well
as increased mesangial and vascular IgG, IgM, and C3 deposits, suggesting a role of Nrf2
in autoimmunity-associated kidney injury [228]. In murine LN, the administration of
sulforaphane reduced the NFκB-mediated inflammatory response [200]. Interestingly, in
an experimental model of LN, sulforaphane and DMF showed stronger anti-inflammatory
and nephroprotective effects in comparison with prednisolone, indicating that Nrf2 in-
duction could be a therapeutic target in patients with glucocorticoid-resistant LN [229].
In two different models of LN (B6.Sle1.Sle3 and MRL.lpr mice), bardoxolone methyl
decreased glomerulonephritis by reducing the activity of the Mitogen-activated protein
kinase/extracellular signal-regulated kinase 1 and 2 (MEK-1/2), ERK, and Signal trans-
ducer and activator of transcription 3 (STAT-3) signaling pathways and decreasing ROS
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production [230]. In this pathological context, melatonin and epigallocatechin-3-gallate
increased Nrf2 expression and decreased the expression of the inflammatory NLRP3 sig-
naling pathway [231,232]. In Nrf2-deficient B6/lpr mice, which are susceptible to LN, Th17
cell activation and STAT3 phosphorylation were increased, while the Th17 differentiation
inhibitor SOCS3 (suppressor of cytokine signal 3) was decreased, indicating a protective
role of Nrf2 in LN [233].
In mice with IgAN, treatment with the Nrf2-inducer osthole reduced inflammatory
cell infiltration and the activation of the NF-κB and NLRP3 signaling pathways [234].
Similar results were observed in experimental FSGS with the Nrf2 inducers antroquinonol,
osthole, citral, or astaxanthin [207–210]. In murine crescentic GN, epigallocatechin-3-gallate
increased nuclear Nrf2 translocation and modulated the p-Akt, p-JNK, p-ERK1/2, and
p-p38 intracellular pathways, with subsequent reduction in lymphocyte and macrophage
infiltration [213].
6.3. Nrf2 Activation Reduces Fibrosis in CKD
Nrf2 activation and subsequent expression of Nrf2-related genes have been reported
in UUO mice, one of the most used experimental models to study renal fibrosis [221,235].
In UUO mice, Nrf2 deficiency increased tubular damage, fibrotic markers (TGF-β1, fi-
bronectin, α-SMA) and inflammatory cytokines/chemokines (TNF-α, IL-6, IL-1β) and
macrophage infiltration, while decreasing the antioxidant response [191]. Keap1 hypo-
morphic mice, characterized by Nrf2 hyperactivation, showed milder renal fibrosis after
UUO [236]. Treatment with several Nrf2 inducers, including sulforaphane and DMF, de-
creased renal fibrosis in UUO mice [237–239]. Importantly, the anti-fibrotic effects of the
Nrf2 inducers were observed in wild-type mice, but not in Nrf2-deficient mice, suggesting
the specific involvement of this signaling pathway against fibrosis [222]. Rats with subtotal
nephrectomy, a well-characterized model of CKD, also showed decreased renal fibrosis
after treatment with the Nrf2 inducers curcumin and bardoxolone [217–219,240].
DN has also been related to renal fibrosis. Nrf2-/- mice with streptozotocin-induced
diabetes showed increased glomerular fibrosis (higher TGF-β1, type I and IV collagen,
and fibronectin levels) and lower creatinine clearance in comparison to wild-type diabetic
mice [241,242]. In DN mice, the C66 curcumin analog prevented kidney fibrosis and
downregulated fibrosis-related mediators (Connective tissue growth factor (CTGF) and
Plasminogen activator inhibitor-1 (PAI-1)) [243]. In diabetic mice, sulforaphane increased
the expression of Nrf2 and NQO-1, decreased oxidative stress, and reduced the levels of
fibrotic mediators such as TGF-β1, CTGF, and PAI-1 [226]. In cultured mesangial cells
exposed to high glucose concentrations, sulforaphane reduced the fibrotic response through
modulation of GSK3β/Fyn/Nrf2 signaling, resulting in downregulation of TGF-β1, type IV
collagen, and fibronectin gene expression [244,245]. The anti-fibrotic effects of sulforaphane
were abolished when GSK3β levels were elevated, whereas pharmacological inhibition of
GSK3β led to opposite results [244]. In the streptozotocin-induced DN model, sulforaphane,
cinnamic aldehyde, and digitoflavone preserved renal function and decreased glomerular
damage and fibrosis in an Nrf2-dependent manner [246,247]. Co-treatment with resveratrol
and rosuvastatin in streptozotocin-induced DN re-established kidney Nrf2 levels and
reduced TGFβ1 and fibronectin gene expression as well as urinary TGFβ1 levels [199].
Another compound, AB38b, ameliorated experimental DN, including decreased type IV
collagen deposition via the Keap1/Nrf2 signaling pathway [245].
In a mouse model of LN, sulforaphane improved renal function and reduced the levels
of TGFβ1, fibronectin, and iNOS [200]. In experimental FSGS, Keap1 knockdown mice
displayed milder glomerulosclerosis (as reflected in decreased desmin-positive injured
podocytes, and decreased gene expression of TGFβ1, fibronectin, Col4a4, and Col1a2),
and preserved nephrin expression, indicating a beneficial impact of Nrf2 activation [248].
In adriamycin-induced FSGS, 2,3,5,4′-tetrahydroxystilbene-2-O-β-d-glucoside (THSG) de-
creased albuminuria, lipid peroxidation, podocyte injury, renal fibrosis, and glomeruloscle-
rosis, and induced Nrf2 nuclear translocation and HO-1 and NQO-1 gene expression [249].
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6.4. Nrf2 and Uremic Toxins
In CKD patients, the accumulation of uremic toxins contributes to CKD manifesta-
tions [250,251]. Uremic toxins may modulate Nrf2 expression and function. However, the
exact role of Nrf2 in this pathological context is not clear. In an experimental model of subto-
tal nephrectomy, the endogenous uremic toxin indoxyl sulfate reduced Nrf2 expression [252].
However, the exogenous uremic toxin Bisphenol A promoted mitochondrial dysfunction
and oxidative stress in cultured tubular cells, an effect that was associated with Nrf2 activa-
tion and expression of Nrf2 target genes such as HO-1 and NQO-1 [253]. Therefore, further
studies are warranted to clarify the role of Nrf2 in this pathological context.
7. Clinical Trials Targeting Nrf2
Several clinal trials have studied or are now exploring the effect of Nrf2 inducers
on CKD or DN (Table 4). Among them, the most complete data refer to bardoxolone
methyl. Following an exploratory phase 2 clinical trial (NCT00664027) [254], the BEAM
study (NCT00811889), a phase 2 clinical trial, showed that bardoxolone methyl increased
GFR in patients with diabetic nephropathy [255]. However, it increased blood pressure
and albuminuria [255]. These results were confirmed in a phase 3 clinical trial (BEACON
study, NCT 01351675), in which diabetic nephropathy patients with CKD (stage 4) were
enrolled [256]. Of note, the BEACON study was terminated prematurely due to a higher
rate of cardiovascular events among patients treated with bardoxolone [256]. Although the
cause of these adverse cardiovascular outcomes remains unclear, it has been postulated
that a reduction in endothelin levels [257] could be associated with fluid retention [258]
and heart damage/failure in CKD patients [259,260]. In the TSUBAKY study, a phase 2
clinical trial in Japanese type 2 diabetic patients with CKD (stage3/4) bardoxolone treat-
ment increased GFR, creatinine clearance, and urinary albumin to creatine ratio, without
major security concerns (NCT02316821) [261]. An ongoing phase 3 trial is exploring the
effectiveness and safety of bardoxolone in Japanese diabetic CKD patients to test whether
cardiovascular effects side-effects of bardoxolone may be milder in Japan (AYAME study,
NCT03550443). The trial is expected to be completed in 2022. New clinical trials are
determining the possible beneficial effects of bardoxolone in younger CKD patients with
fewer cardiovascular comorbidities than diabetic patients. Thus, a phase 2 clinical trial is
being conducted to explore the effects of bardoxolone in CKD patients with type 1 diabetes,
IgAN, Focal Segmental Glomerulosclerosis (FSGS), or Autosomal Dominant Polycystic
Kidney Disease (ADPKD) (PHOENIX study, NCT03366337). Moreover, ongoing clinical
trials are being performed to determine the effect of bardoxolone in patients with Alport
syndrome (CARDINAL study, NCT03019185), or CKD patients with ADPKD or Alport
(EAGLE study, NCT03749447). Finally, the phase 3 FALCON clinical trial is exploring
whether bardoxolone may be useful in patients with autosomal dominant polycystic kidney
disease (FALCON study, NCT03918447).
Other clinical trials have evaluated the protective role of natural Nrf2 inducers in renal
patients, although the beneficial effects are not clear. The impact of curcumin (320 mg/day)
was tested in a placebo-controlled phase 3 clinical trial in proteinuric CKD patients with
or without diabetes, but no effects on Nrf2 activation, antioxidant enzyme activity, pro-
teinuria, eGFR, or lipid profile were reported (NCT01831193) [262]. A phase 2 clinical
trial by the same group testing a higher dose of curcumin (1670 mg/day) should have
been completed in 2017, although no results have been posted (NCT03019848). Surpris-
ingly, a second placebo-controlled trial, testing a lower dose of curcumin (66 mg/day) for
two months reported decreased proteinuria, and lower serum TGF-β1 and IL-8 levels in
20 type 2 diabetics with proteinuric CKD (NCT01015937, not FDA-defined phase) [263]. A
new clinical trial is now recruiting CKD patients to determine whether curcumin intake
reduces inflammation and oxidative stress (NCT03475017, not FDA-defined phase). An
ongoing phase 2/3 clinical trial is also evaluating the interaction between the rs35652124
polymorphism in the NFE2L2 gene and curcumin supplementation on Nrf2 expression,
oxidative stress, and renal function in early diabetic nephropathy patients (NCT03262363).
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Table 4. Summary of clinical trials with Nrf2 inducers in CKD.
Status Disease Compound Results Clinical Trial Phase References
Ongoing
CKD








BDM - AYAME,NCT03550443 3
Alport BDM - CARDINAL,NCT03019185 2/3
CKD, ADPKD
and Alport BDM -
EAGLE,
NCT03749447 3
ADPKD BDM - FALCON,NCT03918447 3
Completed
CKD and T2D













No beneficial effects NCT01831193 3 [262]
Decreased








BDM Not shown PHOENIX,NCT03366337 2








(safety reasons) NCT01549769 1
Interrupted
(safety reasons) NCT01500798 1
Curcumin Not shown NCT03019848 2




A randomized, double-blind, placebo-controlled phase 1 clinical trial reported that
500 mg of resveratrol along with losartan reduced albuminuria and insulin resistance
without modifying GFR in 30 type 2 diabetic patients with microalbuminuria. Treatment
with losartan alone did not show positive effects (NCT02704494) [264]. While the results
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appear promising, there are inconsistencies in the data from this small short-term trial,
since resveratrol improved insulin sensitivity while, surprisingly, losartan alone did not
reduce albuminuria. No ongoing trials are testing resveratrol for diabetic nephropathy,
according to clinical trials.gov.
8. Overactivation of the Nrf2 Pathway: Paradise or Hell?
Activation of the Nrf2 signaling pathway is one of the main cytoprotective mechanisms
against oxidative stress in renal cells, thus decreasing the progression of kidney disease
(Figure 3). Extensive literature has demonstrated the beneficial effects of Nrf2 activation
in other pathologies, such as fatty liver disease [265], cardiovascular diseases [266], dia-
betes [267], neurodegenerative diseases, as well as Hutchinson-Gilford Progeria Syndrome
(HGPS), a rare genetic disease characterized by accelerated aging [268,269]. However, over-
activation of the Nrf2 pathway, as well as constitutive maintenance of the Nrf2 response,
could be associated with progressive tissue damage [270,271]. Thus, increased expression
of Nrf2 in tumors is an unfavorable prognostic factor [272,273]. In relation to renal disease,
a recent study showed that even though Nrf2 activation increased antioxidant enzymes, it
caused proteinuria in CKD mice [274]. Similarly, excessive activation of Nrf2 after treat-
ment with the bardoxolone methyl analogs RTA 405 and dh404 increased proteinuria and
glomerulosclerosis in DN rats [275]. In diabetic obese Zucker rats, high-dose of RTA dh404
also triggered proteinuria and renal pathological features [276]. Importantly, diminished
atherosclerosis associated with diabetes and decreased functional and structural glomerular
and tubular injury were observed in diabetic mice treated with a low-dose of RTA dh404,
while treatment with a high dose was deleterious [277].
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Figure 3. Activation of the Nrf2 signaling pathway in kidney diseases. Several nephrotoxic stimuli, such as ROS, proteinuria,
hyperglycemia, uremic toxins, or inflammation, promote Nrf2 activation in the kidney (fibroblasts, infiltrating leucocytes,
tubuloepithelial, glomerular and endothelial cells). Activated Nrf2 induces the expression of phase II enzymes and inhibits
the activation of intracellular pathways associated with renal injury (MAPKs, p38, JUN, ERK, JAK/STAT, NF-κB, TLRs),
reducing oxidative stress, cell death, inflammation, and fibrosis.
Antioxidants 2021, 10, 39 19 of 31
To date, the strongest data regarding the potential clinical impact of Nrf2 activators
have been obtained in clinical trials with bardoxolone. The results are robust regarding the
increased GFR but are at odds with some studies linking the upregulation of Nrf2 with
proteinuria and high blood pressure. This is a key aspect given the increased cardiovascular
mortality rate in CKD patients [278]. For that reason, the latest clinical trials (AYAME,
EAGLE and CARDINAL) have included younger CKD patients, at earliest CKD stages,
and with fewer cardiovascular comorbidities.
9. Conclusions
Oxidative stress is involved in both the pathogenesis and progression of kidney
diseases. Nrf2 is a master transcriptional regulator for genes related to redox status,
decreasing oxidative stress and inflammatory response. Remarkable beneficial effects
due to N2 activation in the prevention of renal disease progression have been noted in
a number of experimental studies. Recent clinical trials targeting Nrf2 in renal diseases
have demonstrated outstanding beneficial effects improving renal function in patients
with diabetes and CKD stage 3, an effect unseen with any other therapeutic approaches.
The ongoing clinical trials in other kidney diseases, beyond diabetic nephropathy, and the
design of additional novel trials including a larger number of patients and longer outcome
duration would contribute to set up Nrf2 as one of the most promising therapeutic targets
for kidney disease, an area with scarce number of novel medications.
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